The extent to which European authorities must go to justify allegations of abuse of a dominant position by pharmaceutical firms is once again in the spotlight, with a potential recalibration on the horizon in the wake of the latest opinion from an advocate general of the Court of Justice of the EU.
In the latest instalment of a long-running dispute over Servier’s patent-litigation settlement deals with multiple generics firms over perindopril, advocate...






